Sharemaestro Newsreel

Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis

The financial score for Evolus Inc (EOLS) is 8.00, placing it 82nd out of 155 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a 6.74% year-over-year increase in its latest quarterly revenue to $73.14M and a …

Amphastar Pharmaceuticals (AMPH) Projected to Release Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (AMPH) is expected to release its Q2 2026 earnings after market close on Thursday, August 6th, with analysts projecting $0.66 EPS and $179.9210 million in revenue. The company previously missed Q1 2026 consensus estimates, reporting $0.42 EPS against an anticipated $0.70. Institutional …

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, setting the foundation for next wave of medicines No change to …

Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis

Amylyx Pharmaceuticals Inc (AMLX) has a weak financial status with a score of 5.42, ranking 360 out of 384 in its industry. The company's operational efficiency is low, and key financial data for metrics like cash and cash equivalents, total revenue, and free cash …

Amneal Reports Second Quarter 2026 Financial Results

Amneal Pharmaceuticals reported strong second quarter 2026 financial results with net revenue up 10% to $796 million and adjusted EBITDA increasing 12% to $206 million. The company raised its full-year 2026 guidance, citing broad-based performance and confidence in its diversified portfolio, including anticipated contributions …

Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Elanco Animal Health Inc (ELAN) as of July 29, 2026. The company has a current valuation score of 9.25, ranking 37th in the Pharmaceuticals industry, and its P/E ratio is -54.06. Key valuation metrics like P/B, P/S, …

Viatris Inc (VTRS) Risk Assessment: Volatility, Financial Risk & Investment Risk

Viatris Inc (VTRS) has a current risk assessment score of 8.80, placing it 21st out of 155 in the Pharmaceuticals industry. The company's beta of 0.89 indicates it tends to underperform during market uptrends but experiences smaller declines during downturns. The report details various …

Talphera Inc (TLPH) Financial Health: Profitability & Balance Sheet Analysis

Talphera Inc (TLPH) has a weak financial status and low operating efficiency, ranking 154 out of 155 in the Pharmaceuticals industry with a financial score of 5.43. The company reported a 100% year-over-year decrease in quarterly revenue and a 1.43% decrease in net profit. …

Tilray Brands Number of Employees 2026 | Employee Count & Headcount Data

Tilray Brands (NASDAQ: TLRY) had approximately 2,732 employees worldwide as of March 2026, marking a 15.0% decline since 2023. Despite the reduction in headcount, the company is actively hiring and had 170 active job postings in 2026, a 34.5% increase from 2025. The workforce …

Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), detailing its current price momentum, support and resistance levels, and various technical indicators. The stock's price momentum score is 3.43, and it is trading between a resistance level of $8.98 and a …

Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis

Citius Oncology Inc (CTOR) currently holds a financial score of 7.83, placing it 79th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The report notes that relevant financial data for key metrics like …

SIGA Technologies Inc (SIGA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for SIGA Technologies Inc (SIGA), detailing its volatility, financial risk, and investment risk. It notes that SIGA has a risk assessment score of 5.23, ranking 71st in the Pharmaceuticals industry, and a beta of 0.92, indicating it tends …

OrganiGram Holdings Inc (OGI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of OrganiGram Holdings Inc (OGI), focusing on its current stock price momentum, support and resistance levels, and various technical indicators. It details how OGI is trading between resistance at $1.05 and support at $0.83, making it suitable for …

SIGA Technologies Inc (SIGA) Institutional Confidence

The article analyzes the institutional confidence score for SIGA Technologies Inc (SIGA), which stands at 5.00, placing it 72nd in the Pharmaceuticals industry. Institutional shareholding proportion increased by 10.57% quarter-over-quarter, with HOTCHKIS & WILEY as the largest institutional shareholder despite a slight decrease in …

Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Sonoma Pharmaceuticals Inc (SNOA), detailing its current risk score of 3.07 within the Pharmaceuticals industry. Key metrics such as beta value, maximum drawdown, volatility, and various return and liquidity indicators are presented. The assessment highlights the stock's …

Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 net product revenue guidance to a …

RMTI: Reverse Split And New Contracts Will Support Future Rebound

Rockwell Medical (RMTI) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. In response, the company has approved a reverse stock split and analysts have significantly increased their price target to $30.00 per share, citing updated financial assumptions and …

TXMD|TherapeuticsMD Inc|Price:2.070|Chg%:+0.010

This article provides a detailed stock analysis of TherapeuticsMD Inc (TXMD), highlighting its healthy fundamentals, high growth potential, and fair valuation. While institutional ownership is very high, the stock is currently trading sideways. The company operates as a pharmaceutical royalty company, collecting royalties from …

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Pacira BioSciences released findings from its "Standing Strong: The Impact of Pain on America's Workforce" survey, highlighting that 85% of workers in physically demanding jobs experience pain while working, with chronic knee pain being a prevalent issue. The survey revealed significant impacts on income, …

Curium Reportedly Nears Acquisition Of Lantheus For Approximately $7 Billion

Curium Pharma is reportedly in advanced discussions to acquire radiopharmaceutical company Lantheus Holdings for approximately $7 billion, with potential for up to $8 billion through contingent value rights. This acquisition would merge two major nuclear medicine and diagnostic imaging companies, aiming to create a …

Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aytu Biopharma Inc (AYTU), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of July 29, 2026, AYTU's price momentum score is 3.08, and the stock is trading …

Alkermes (ALKS) Stock Revenue Jumps While Margins Lose Steam

Haleon posts in-line quarterly sales growth as oral health, North America drive demand

Haleon reported a 3.1% organic sales growth in the second quarter, matching estimates, fueled by strong demand for its oral health products and accelerated growth in North America. The company reaffirmed its 2026 forecast for 3% to 5% organic revenue growth and high-single-digit adjusted …

LQDA|Liquidia Corp|Price:85.495|Chg%:-1.325

This article provides a comprehensive stock analysis of Liquidia Corp (LQDA) from TradingKey, highlighting that its fundamentals are strong with high growth potential, and its valuation is considered fairly valued within the Pharmaceuticals industry. Despite strong fundamentals and stock performance, technical indicators show the …

Bausch Health Cos Q2 Earnings Call Highlights

Key Points Interested in Bausch Health Cos Inc.? Here are five stocks we like better. Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch + Lomb, revenue rose 16% to $1.458 billion and adjusted EBITDA increased 28% to $865 million. …

Tilray Brands (TLRY) Stock Revenue Growth Clashes With Persistent Losses

Tilray Brands (TLRY) reported increased revenue and narrowed losses for FY2026, with Q4 revenue up 25% and net loss significantly reduced. Despite financial improvements and a strong balance sheet, the company still posted a net loss of US$121.4m for the full year and experienced …

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported $2.85 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.7%. EPS of $1.26 for the same period compares to $0.90 a year ago. The reported revenue represents a surprise of +7.62% over the Zacks …

Analysts Expect Eton Pharmaceuticals, Inc. (NASDAQ:ETON) To Breakeven Soon

Analysts are optimistic about Eton Pharmaceuticals (NASDAQ: ETON) achieving breakeven soon, driven by strong growth in its pharmaceutical products. The company is projected to reach profitability by 2027, with revenue expected to increase significantly over the next few years. Despite a recent dip in …

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical, Inc. announced that it will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. The company's senior management team will host a webcast at 8:00 a.m. Eastern Time on the …

Teva outlines higher 2026 revenue midpoint by $75M while targeting AUSTEDO $2.45B-$2.6B and AJOVY $850M-$870M

Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 MANAGEMENT VIEW * "On delivery on our growth engines, AUSTEDO, AJOVY, and UZEDY all delivered strong Q2 performance, and we are raising our full-year revenue guidance for these products." (President, CEO & Director Richard …

Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline

Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to …

Bausch: Q2 Earnings Snapshot

Evolus Shareholder Alert

Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Evolus, Inc. following a federal securities class action lawsuit. The lawsuit alleges that Evolus made false statements regarding the origin of its Jeuveau™ product and misappropriated trade secrets from Medytox. This …

How Evolus Inc. (EOLS) Affects Rotational Strategy Timing

This article analyzes Evolus Inc. (EOLS) utilizing AI models to provide insights for a rotational strategy. It highlights a near-term strong sentiment challenging persistent mid and long-term weakness and identifies a significant risk-reward setup. The analysis offers three distinct institutional trading strategies—Position, Momentum Breakout, …

Haleon plc Revenue Breakdown – NYSE:HLN